Table 3.
Pre-salvage imaging characteristics.
| No. Patients (%) | ||
|---|---|---|
| MRI | ||
| Median prostate size (mL) a | 28.3 (25.0–37.7) | |
| Median tumor diameter (mm) a | 13.0 (10.0–19.5) | |
| Tumor location | Base | 7 (17.1) |
| Midgland | 11 (26.8) | |
| Apex | 6 (14.6) | |
| Overlapping | 4 (9.8) | |
| Seminal vesicle | 5 (12.2) | |
| Prostate and seminal vesicle | 8 (19.5) | |
| Tumor side | Left | 11 (26.8) |
| Right | 18 (43.9) | |
| Bilateral (midline) | 9 (22.0) | |
| Bilateral (multifocal) | 3 (7.3) | |
| PI-RADS | 2 | 1 (2.4) |
| 3 | 4 (9.8) | |
| 4 | 16 (39.0) | |
| 5 | 20 (48.8) | |
| PSMA PET/CT | ||
| Median SUV max a | 6.9 (4.8–12.1) | |
| Tumor location | Base | 7 (17.1) |
| Midgland | 11 (26.8) | |
| Apex | 6 (14.6) | |
| Overlapping | 4 (9.8) | |
| Seminal vesicle | 5 (12.2) | |
| Prostate and seminal vesicle | 8 (19.5) | |
| Tumor side | Left | 13 (31.7) |
| Right | 18 (43.9) | |
| Bilateral (midline) | 7 (17.1) | |
| Bilateral (multifocal) | 3 (7.3) | |
| Imaging TNM stage | ||
| T | T2 | 29 (70.7) |
| T3 | 12 (29.3) | |
| N | N0 | 41 (100) |
| M | M0 | 39 (95.1) |
| M1 | 2 (4.9) | |
a: Expressed as median with interquartile range. PI-RADS: Prostate Imaging—Reporting and Data System. PSMA: prostate specific membrane antigen. SUV: Standard Uptake Value. TNM: TNM Classification of Malignant Tumors.